December 15,Shanghai Hengrun Dasheng Biotechnology Co., Ltd. AnnouncesDr. Zheng Biao joins to oversee R&D and medical affairs, responsible for the full-process management of new drug development from exploratory research, preclinical studies to clinical trials.Data shows that Dr. Zheng Biao graduated from the Department of Medicine at Zhejiang University School of Medicine with a Bachelor's degree in Clinical Medicine. He subsequently obtained a Master’s degree in Immunology from Fudan University School of Medicine in Shanghai and a Ph.D. in Immunology from King's College London.
Formerly taught at the University of Maryland School of Medicine and Duke University Medical Center; subsequently served at Baylor College of Medicine in the United States as a tenured professor in the Department of Pathology and Immunology. Dr. Zheng Biao has an extensive list of academic publications, with numerous papers published inNatureAndSciencein top-tier journals around the world.
In 2010, Dr. Zheng Biao joined the R&D center of global pharmaceutical giant GSK China, focusing on the field of immunology.Along the research.In 2015, he assumed the role of Global Vice President at Johnson & Johnson, taking full responsibility for the research and development of innovative drugs in the immunology field across the Asia-Pacific region, with a strategic focus on cancer immunotherapy and autoimmune disease treatment.Upon joiningBefore Shanghai Hengrun Dasheng Biotechnology Co., Ltd.,Dr. Zheng BiaoHe also served as the Chief Scientific Officer of IASO Biotherapeutics and the Chief Executive Officer of Shanghai Bond Biological Technology Co., Ltd., accumulating valuable leadership and practical experience in cutting-edge biotechnology fields such as cell and gene therapy.Shanghai Hengrun Dasheng Biotechnology Co., Ltd. is an innovative pharmaceutical company focused on the research, development, and production of immune cell therapy products. Since its establishment in 2015, the company has been dedicated to the treatment of malignant hematological diseases and solid tumors for a decade.Shanghai Hengrun Dasheng Biotechnology Co., Ltd., as a biopharmaceutical enterprise planning to adopt the fifth set of listing standards for the STAR Market, has attracted significant external attention.On July 30, 2025, the official website of the National Medical Products Administration (NMPA) announced that the New Drug Application (NDA) for Reniucel Injection (brand name: Hengkailai®, English brand name: HICARA®), a Class 1 innovative biologic product developed by Shanghai Hengrun Dasheng Biotechnology Co., Ltd. ("Hengrun Dasheng"), has been approved.It is reported that this product is China's first completely self-developed CD19 CAR-T product for relapsed or refractory large B-cell lymphoma (r/r LBCL). It marks that China’s immune cell therapy technology has entered a new stage of full autonomy and control, providing solutions for more unmet clinical needs.↓⭐Follow PharmaTribune, Insight into Industry Trends ↓Submission/Corporate Cooperation/Content Communication:Editor-in-Chief of Yaotong Society—Huaji Meiren (Ww_150525)*Please indicate remarks and purpose when adding.
